INTRODUCTION

Systematic identification of the causal von Willebrand disease (VWD) mutations has been
hampered by the large size of the von Willebrand factor gene (VWF), which is highly polymorphic and has a greatly homologous partial pseudogene (1) . Because of these difficulties, molecular study of VWD has been confined mainly to basic investigation.
Current sequencing technology has allowed only several expert laboratories to perform VWF sequencing in patients with VWD (2-4).
The cost of traditional sequencing based on the Sanger method remains a serious obstacle for most diagnostic laboratories. However, perspectives in molecular diagnosis of monogenic diseases have radically changed over the last years with the introduction of new massively parallel next-generation sequencing (NGS) platforms that are considered alternatives or complementary to traditional sequencing (5) . Systematic re-sequencing of genes that have been implicated in related Mendelian diseases is a promising strategy for identifying risk factors for complex diseases (6) . Moreover, next generation sequencing (NGS) technology also could facilitate the identification of mutations in patients with monogenic diseases. Although NGS is undoubtedly superior in throughput to Sanger sequencing, it has had yet little impact on monogenic disease diagnostics (7) (8) (9) . To take advantage of this new technology for molecular diagnosis of VWD, we designed a procedure for fast, low-cost characterization of a large number of samples, derived from a highly optimized method developed in our laboratory (4) . A proof-of-concept study was performed using an NGS platform. The results demonstrate a high performance DNA sequencing of VWF in a large number of VWD patients and their families and establishes the basis for performing a large-scale sequencing study in an affected population.
DESIGN AND M ETHODS
Patients
Samples were collected and clinical data compiled from 40 unrelated patients of several origins with different types of VWD. Most patients had been diagnosed at the Hemophilia Unit of Vall d'Hebron Hospital (Barcelona); the ISTH criteria were met in all cases (10, 11).
Peripheral blood samples were collected in tubes of 4 ml containing ACD or EDTA.
Genomic DNA was isolated from 300 µl of blood with the FlexiGene DNA Kit (Qiagen, Duesseldorf, Germany). The study was approved by the ethics committee of Vall d'Hebron Hospital, and all patients provided informed consent for participation.
PCR enrichment and Normalization
Genomic DNA in equimolar concentrations from every 5 patients was mixed and subjected to the conventional short PCR amplification according to our previously described procedure (4) . All the coding regions and flanking intronic regions of VWF (~10 Kb) are included ( Figure 1A ). Normalization of amplicons was done by gel quantification performed with ImageJ (Version 1.43u), a public domain Java image processing program (http://rsbweb.nih.gov/ij/). By taking a sample with a known concentration as the control, it was possible to extrapolate the concentration of each sample to create a normalized pool of the 47 PCR products in one tube. This pooling process gives rise to 8 tubes and each tube derives from the simultaneous amplification of VWF of 5 patients.
PCRs fragmentation, Massively Parallel Sequencing and Bioinformatic analysis
In NGS, the fragmentation step is critical for the success of the sequencing process, and must be performed according to stringent parameters. Because the commonly used mechanical systems for genomic DNA fragmentation such as sonication are not effective for short DNA fragments (eg, <300-500 bp) (12), conventional short PCRs were fragmented by heat incubation at 95ºC for 9 hours ( Figure 1B ) followed by one hour of re-annealing at 72°C. This provided efficient DNA fragmentation that was relatively unbiased, as required for Illumina GA sequencing procedures (12). All samples were purified using the QIAquick DOI: 10.3324/haematol.2011.055285 PCR Purification Kit (Qiagen) and the size distribution of the fragments was checked using a DNA 100 chip on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Subsequent massively parallel sequencing and bioinformatic analysis was performed according to the described in the Online Supplementary Methods.
Mutation assignment
To confirm the mutations identified by NGS and assign them to patients, the specific region including the mutation was PCR-amplified and sequenced by dideoxynucleotide method, as described (4). The sequences obtained were assembled and aligned against the consensus wild-type VWF sequence using SeqScape (v2.7) software (Applied Biosystems, Foster City, CA, USA).
RESULTS AND DISCUSSION
Based on the conclusions from a pilot study (Online Supplementary Appendix), a proof-ofconcept study was performed for the simultaneous analysis by NGS of 40 VWD patients previously diagnosed and classified according to their clinical characteristics ( Table 1) . The mutations responsible for the disease were known in 8 of the selected patients, who had been characterized by Sanger sequencing (4) and were used as controls. Patients included in this study were randomly selected from all those who met the criteria for VWD, to obtain a representative picture of the types, percentages, and variability of patients usually seen at the Hemophilia Unit.
NGS technologies are truly advantageous from the economic viewpoint when the sequencer runs completely full, which, in the case of short region sequencing (eg, VWF), means including the maximum number of samples (15) and the preparation of one sequencing library per sample. However, library construction is one of the most expensive steps in the overall NGS process. Thus, when the study was conceived, we contemplated and prioritized minimizing the number of libraries constructed per flow cell lane.
Consequently, genomic DNA in equimolar concentrations from every 5 patients, including one control patient per pool, was mixed and subjected to the conventional short PCR amplification described above (4). After amplification, normalization, and pooling of amplicons, the process yielded 8 tubes, each representing 5 patients. Illumina's library construction protocol was performed for each of the 8 tubes, inserting 8 different pentanucleotide sequences as index tags (i.e., 1 tag for every 5 patients). Sequence tagging allows software-mediated segregation and independent analysis of the sequences.
Thus, 40 patients could be analyzed in 1/8 of the Illumina flow cell, representing a considerable cost reduction. As a preliminary approach, we amplified genomic DNA from 5 patients mixed together, considering that for a single heterozygous variant allele in a pool of 5 diploid individuals one would expect 10% of the reads to carry the variant allele. A drawback to this strategy is that pooling genomic DNA before PCR amplification results in a waste of the information on SNPs for each patient obtained with the Sanger sequencing DOI: 10.3324/haematol.2011.055285 method. However, it is possible to save this information with NGS using novel, innovative approaches such as microfluidics technology (16) that can also be explored by introducing slight modifications to our current protocol.
Analysis of the sequences obtained by NGS for each group of 5 patients allowed detection of a variable number of potential mutations (3-9) that were further corroborated and assigned to the right patient by sequencing the corresponding exons (3) (4) (5) (6) in all patients included in the pool. The results of this analysis are shown in Table 1 . Excluding pool H (control patient VW0141 carrying the mutation c.4120C>T), all mutations from the control patients (last row of each pool) were detected by NGS. This pool had an unidentified problem somewhere in the sequencing process that resulted in low overall coverage.
Although we did not systematically study the cause, differences in tag performance have been described previously (13) and could be the likely explanation. Therefore, VWF from patients in this pool were entirely sequenced by the Sanger method, and the mutations detected were identical to those detected by NGS, except for the above-mentioned c.4120C>T. With the current analytical parameters used in the CLC Genomics Workbench (see Online Supplementary Methods), we detected 2 mutations by NGS (c.1588A>C and c.3231C>G) in several pools (C, D, E and G) that could not be confirmed by Sanger sequencing, and were, therefore, false-positive. Probably such false-positive calls were the result of systematic bias since they were present in more than one sample. This limitation has been reported previously for NGS and is mainly associated (>70% of the cases) with repetitive elements, a homopolymer stretch ≥6 bases, simple repeats, and/or the presence of an indel in the vicinity (17) . Nevertheless, analysis of sequence contexts for mutation c.1588A>C (p.N530H) and c.3231C>G showed that they do not have associated such elements. Additional controls ruled out potential contamination, so we consider these mutations artifacts, although we cannot suggest a likely explanation for this occurrence at this time.
Furthermore, after mutation assignment, we were unable to identify any genetic variations in 11 of the 40 (27.5%) VWD patients studied. VWF of these patients was entirely DOI: 10.3324/haematol.2011.055285 sequenced by Sanger method and a mutation was detected in only 2 cases; there was no detectable mutation in the remaining 9 cases. Multiplex ligation-dependent probe amplification (MLPA) (14) was applied to all these 9 cases and only patient VW0057
showed an abnormal MLPA pattern, revealing a heterozygous deletion of exon 15. The point mutations identified by Sanger sequencing and not by NGS (false-negative mutations) were a substitution in patient VW0141 (c.4120C>T) and the duplication of an aminoacid (c.4678_4680dup, p.D1560dup) in patient VW0078. Moreover, in VWF from the type 3 patient VW0276, only one mutation that did not explain the severe phenotype was detected by NGS, so complete sequencing by Sanger was also done. Remarkably, the second mutation detected in this patient was the duplication of 4 bases (c.6699_6702dup).
Accordingly, we achieved encouraging results with high efficiency in mutation detection.
The only problem we encountered was detecting insertions of three or more bases. These results are likely related to the software analysis rather than the sequencing procedure, because all point mutations were positively detected in pools with optimal coverage conditions. It is known that indel detection using NGS platforms is technically challenging.
Misalignments and/or low coverage can lead to missed frameshift insertion calls (17) , which occurred in two of the patients we studied. To avoid this, the use of paired-end sequencing libraries rather than single read runs can be used to detect large and small insertions, deletions, inversions, and other rearrangements. Nevertheless, the rate of false-positive and false-negative mutations is currently a significant drawback for these platforms, hence, it is still essential the validation of mutations by Sanger sequencing. However, cost-reduction allowed by NGS could change this picture: the combination of massively parallel mutation analysis together with phenotypic and familial data in a welldefined population will be very useful for better understanding of the mechanisms involved in the pathophysiology of the type 1 VWD.
In conclusion, our study shows that, even with the existing difficulties, individual researchers can use NGS as a research tool with confidence and ease. To our knowledge, this is the first report in which NGS re-sequencing is examined in genetic study of multiple patients with a congenital monogenic disease. Hence, this approach can serve as an example for other coagulopathies or disorders linked to large and complex genes in order to convert NGS to a routine diagnostic reality in the near future.
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B. Potential Splice Site Mutations (PSSM)
Nucleotide
Long-range PCR enrichment
A new procedure for VWF amplification has been designed based on LR-PCR and subsequent application to NGS. An accurate analysis of the sequence allowed selection of 14 pairs of specific primers for amplification, covering all exons and a large percentage of intronic regions (Online Supplementary Figure S1A ).
According to our results, the SequalPrep System provides a highly efficient and robust enrichment solution to meet NGS re-sequencing throughput capabilities. Only one of the 14 PCRs designed presented setup problems: LR-PCR number 6, which includes exons 14, 15 and 16, was refractory to amplification under the conditions tested, probably due to the high GC content of this region (5). Amplification of LR-PCR 6 was redesigned to amplify the region in two shorter fragments (6A and 6B), in an attempt to circumvent these difficulties. However, we were only able to efficiently amplify region 6B (covering exon 16
and partially covering introns 15 and 16) (Online Supplementary Figure S1B) . The LRPCRs were then mixed at an equimolar concentration with two conventional PCRs covering exons 14 and 15 and the corresponding flanking intronic regions. After sonication and sequencing, we were able to verify that these regions also have a significant representation in the final sequence obtained. This indicates that nebulization could also be a suitable method for fragmentation of short amplicons prior to library construction. The final protocol established can be adapted to any of the currently available NGS sequencers and allows amplification of 114 Kb, approximately 64% of the VWF sequence.
The sequencing run in the preliminary pilot study was properly developed, and the parameters studied (number of clusters passing filters, percentage of reads aligning to the reference, percentage of error rate after alignment), which were indicative of the quality of the experiment for the 4 samples processed plus the Illumina control library PhiX, did not present any drawbacks and generated the expected clusters with conventional data quality.
Once the run was completed, the sequences were analyzed with Illumina software and exported into BWA, SAMtools, and the CLC Genomics Workbench for variant detection.
The current results indicate that expected mutations and polymorphisms (13 to 17 SNPs)
were identified with high reliability, regardless of the procedure used. Furthermore, in addition to the variations identified by traditional sequencing exons, LR-PCR detected several changes (7, 14, and 8, respectively, in each of the 3 patients) in deep intronic regions that are not described as polymorphisms in dbSNP Build 133 (Online Supplementary Table S2) .
Previous studies have shown that coverage in the 10-to 15-fold range may suffice for resequencing applications, but higher coverage depths provide better alignment, assembly, and accuracy (6). In our case, both the LR-PCR and conventional PCR approaches had higher coverage than needed for a robust re-sequencing assay (Online Supplementary   Table S2 Table S1 ).
After initial denaturation at 94ºC for 2 minutes, 10 cycles were performed at 94ºC for 10 seconds and 68ºC for 18.5 minutes, followed by 20 additional cycles at 94ºC for 10 seconds and at 68ºC for 18. Figure S1 B ).
Normalization and fragmentation of LR-PCRs
Quantitative detection of ethidium bromide-stained PCR product bands by densitometry after agarose gel electrophoresis was used for product quantification. The LR-PCRs were then mixed at an equimolar concentration with two conventional PCRs covering exons 14 and 15 and the corresponding flanking intronic regions. Pools of long-range amplicons were fragmented by sonication with a Bioruptor (Diagenode, Philadelphia, PA).
Massively Parallel Sequencing
Normalized pooled PCR products (5 µg), comprising the amplified sequences of VWF, boundaries covered by PCR products, the CDS sequence for VWF, and the annotated genomic sequence for VWF (GenBank accession NG_009072) were used as reference sequences to detect and assign the previously described mutations and polymorphisms.
To this end, in addition to using the dbSNP Build 133 database, we reviewed the VWF international mutation database (http://www.sheffield.ac.uk/vwf/index.html) and published VWD literature to collect previously described variants clinically associated with the disease.
In silico analysis of novel putative mutations Alamut 1.51 software (Interactive Biosoftware, Rouen, France) was used to investigate the predicted impact of the novel missense mutations described in VWF as a consequence of nucleotide substitution. Missense mutations evaluation include automated access to webbased variant scoring methods (PolyPhen-2, SIFT, Align GVGD) ( (Table 2B) . 
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